论文部分内容阅读
恩曲他滨(emtricitabine,FTC)为胞嘧啶核苷类似物,自2006年始,已先后于欧洲和亚洲完成多中心、随机、双盲、对照研究证实其在慢性乙型肝炎(chronic hepatitis B,CHB)患者中的抗病毒作用[1-2]。FTC多种国产制剂已完成生物等效性试验,被批准用于中国CHB患者的抗病毒治疗[3-4]。为规范FTC的临床应用,《中华实验和临床感染病杂志(电子版)》、《中国肝脏病杂志(电子版)》与《Infection International(Electronic Edition)》编辑部邀请国内相关专家,对FTC相关数据进行汇总讨论,形成《恩曲他滨抗HBV治疗临床应用专家共识》,以供临床医生参考。
Emtricitabine (FTC) is a cytosine nucleoside analogue. Since 2006, a multicenter, randomized, double-blind, controlled study in Europe and Asia has confirmed its role in chronic hepatitis B CHB) patients with antiviral effects [1-2]. A variety of domestic FTC preparations have completed bioequivalence tests and are approved for antiviral treatment in CHB patients in China [3-4]. In order to standardize the clinical application of FTC, “China Experimental and Clinical Infectious Diseases Magazine (Electronic Version)”, “China Journal of Hepatology (Electronic Version)” and “Infection International (Electronic Edition)” editorial department invited domestic experts to FTC related Data summary discussion, the formation of “Emtricitabine anti-HBV clinical application of expert consensus,” for the clinicians for reference.